Version 1
: Received: 22 August 2023 / Approved: 22 August 2023 / Online: 23 August 2023 (09:20:43 CEST)
How to cite:
Correia, V.M.; Herling de Oliveira, L.L.; Junior, V.M.; Rocha, R.G.; O. Leguizamon, J.A.G.; Alves da Costa, L.M.; Fernandes, F.; Krieger, J.E.; Soares, P.R.; Scudeler, T.L. Dilated Cardiomyopathy: A New Era of Treatment. Preprints2023, 2023081645. https://doi.org/10.20944/preprints202308.1645.v1
Correia, V.M.; Herling de Oliveira, L.L.; Junior, V.M.; Rocha, R.G.; O. Leguizamon, J.A.G.; Alves da Costa, L.M.; Fernandes, F.; Krieger, J.E.; Soares, P.R.; Scudeler, T.L. Dilated Cardiomyopathy: A New Era of Treatment. Preprints 2023, 2023081645. https://doi.org/10.20944/preprints202308.1645.v1
Correia, V.M.; Herling de Oliveira, L.L.; Junior, V.M.; Rocha, R.G.; O. Leguizamon, J.A.G.; Alves da Costa, L.M.; Fernandes, F.; Krieger, J.E.; Soares, P.R.; Scudeler, T.L. Dilated Cardiomyopathy: A New Era of Treatment. Preprints2023, 2023081645. https://doi.org/10.20944/preprints202308.1645.v1
APA Style
Correia, V.M., Herling de Oliveira, L.L., Junior, V.M., Rocha, R.G., O. Leguizamon, J.A.G., Alves da Costa, L.M., Fernandes, F., Krieger, J.E., Soares, P.R., & Scudeler, T.L. (2023). Dilated Cardiomyopathy: A New Era of Treatment. Preprints. https://doi.org/10.20944/preprints202308.1645.v1
Chicago/Turabian Style
Correia, V.M., Paulo Rogério Soares and Thiago Luis Scudeler. 2023 "Dilated Cardiomyopathy: A New Era of Treatment" Preprints. https://doi.org/10.20944/preprints202308.1645.v1
Abstract
Dilated cardiomyopathy (DCM) is a common form of cardiomyopathy, characterized by ventricular chamber dilatation and systolic dysfunction, in the absence of coronary artery disease, arterial hypertension, valvular or congenital diseases. DCM is a heterogeneous group of disorders of the myocardium caused by genetic factors, environmental factors, or a combination of both. DCM affects mainly men aged between 20 and 50 years, being considered one of the main causes of heart failure (HF) and the main indication for heart transplantation. Guideline-based HF treatment is the mainstay of management for patients with DCM. In recent years, gene therapy and induced pluripotent stem cells have become promising strategies. In this review, we summarize the relevant clinical issues, and current treatment of DCM patients, including the role of genetic evaluation.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
